feed,title,long_url,short_url
Benzinga,Novartis' Ligelizumab Suffers Setback In Late-Stage Skin Disorder Studies,https://benzinga.com/general/biotech/21/12/24694202/novartis-ligelizumab-suffers-setback-in-late-stage-skin-disorder-studies,https://j.mp/32byXvO
Benzinga,"Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold",https://benzinga.com/general/biotech/21/12/24693977/bluebird-bios-neurodegenerative-disease-gene-therapy-under-priority-fda-review-despite-clinical-h,https://j.mp/3q8QDAh
Benzinga,10 Biggest Price Target Changes For Monday,https://benzinga.com/analyst-ratings/price-target/21/12/24694816/10-biggest-price-target-changes-for-monday,https://j.mp/32i3PKM
